347 related articles for article (PubMed ID: 27812689)
21. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N
J Clin Oncol; 2014 Nov; 32(33):3744-52. PubMed ID: 25332249
[TBL] [Abstract][Full Text] [Related]
23. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
25. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
Pogue-Geile KL; Kim C; Jeong JH; Tanaka N; Bandos H; Gavin PG; Fumagalli D; Goldstein LC; Sneige N; Burandt E; Taniyama Y; Bohn OL; Lee A; Kim SI; Reilly ML; Remillard MY; Blackmon NL; Kim SR; Horne ZD; Rastogi P; Fehrenbacher L; Romond EH; Swain SM; Mamounas EP; Wickerham DL; Geyer CE; Costantino JP; Wolmark N; Paik S
J Natl Cancer Inst; 2013 Dec; 105(23):1782-8. PubMed ID: 24262440
[TBL] [Abstract][Full Text] [Related]
26. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
[TBL] [Abstract][Full Text] [Related]
27. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Romond EH; Perez EA; Bryant J; Suman VJ; Geyer CE; Davidson NE; Tan-Chiu E; Martino S; Paik S; Kaufman PA; Swain SM; Pisansky TM; Fehrenbacher L; Kutteh LA; Vogel VG; Visscher DW; Yothers G; Jenkins RB; Brown AM; Dakhil SR; Mamounas EP; Lingle WL; Klein PM; Ingle JN; Wolmark N
N Engl J Med; 2005 Oct; 353(16):1673-84. PubMed ID: 16236738
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
30. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
31. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.
Tamura K; Shimizu C; Hojo T; Akashi-Tanaka S; Kinoshita T; Yonemori K; Kouno T; Katsumata N; Ando M; Aogi K; Koizumi F; Nishio K; Fujiwara Y
Ann Oncol; 2011 Jun; 22(6):1302-1307. PubMed ID: 21109570
[TBL] [Abstract][Full Text] [Related]
32. [Breast cancer: HER2 changes one's cards on the table].
Lopez M
Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
34. Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Lambertini M; Poggio F; Bruzzone M; Conte B; Bighin C; de Azambuja E; Giuliano M; De Laurentiis M; Cognetti F; Fabi A; Bisagni G; Durando A; Turletti A; Urracci Y; Garrone O; Puglisi F; Montemurro F; Ceppi M; Del Mastro L;
Int J Cancer; 2020 Jul; 147(1):160-169. PubMed ID: 31724170
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
36. Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
Miolo G; Muraro E; Martorelli D; Lombardi D; Scalone S; Spazzapan S; Massarut S; Perin T; Viel E; Comaro E; Talamini R; Bidoli E; Turchet E; Crivellari D; Dolcetti R
BMC Cancer; 2014 Dec; 14():954. PubMed ID: 25512030
[TBL] [Abstract][Full Text] [Related]
37. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
Pivot X; Cortés J; Lüftner D; Lyman GH; Curigliano G; Bondarenko IM; Ahn JH; Im SA; Litwiniuk M; Shparyk YV; Ho GF; Kislov NV; Wojtukiewicz M; Sarosiek T; Chae YS; Ahn JS; Jang H; Kim S; Lee J; Yoon Y
JAMA Netw Open; 2023 Apr; 6(4):e235822. PubMed ID: 37022687
[TBL] [Abstract][Full Text] [Related]
38. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
[TBL] [Abstract][Full Text] [Related]
39. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Nyandoto P; Villman KK; Halonen P; Granstam-Björneklett H; Lundgren L; Sailas L; Turpeenniemi-Hujanen T; Tanner M; Yachnin J; Ritchie D; Johansson O; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
JAMA Oncol; 2018 Sep; 4(9):1199-1206. PubMed ID: 29852043
[TBL] [Abstract][Full Text] [Related]
40. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]